Steady-state bioequivalence study of clozapine tablet in schizophrenic patients

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 8, Issue 1, 2005, Pages 47-53

  Tassaneeyakul, Wongwiwat ^a   Kittiwattanagul, Khanogwan ^b   Vannaprasaht, Suda ^c   Kampan, Jureeporn ^c   Tawalee, Arporn ^c   Puapairoj, Prapawadee ^c   Taimkao, Siriporn ^c   Juthagridsada, Srisaard ^b   Kukongviriyapan, Veerapol ^c   Tassaneeyakul, Wichittra ^c  

^a KHON KAEN UNIVERSITY   (Thailand)

^b Khon Kaen Rajanagarindra Psychiatric Hospital   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLORIL; CLOZAPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERSALIVATION; MALE; MENTAL PATIENT; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TABLET; VOLUNTEER;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CHEMISTRY, PHARMACEUTICAL; CLOZAPINE; CROSS-OVER STUDIES; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 27444437220     PISSN: 14821826     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ereshefsky, L.; Watanabe, M.D. and Tranjohnson, T., Clozapine: an atypical antipsychotic. Clin Pharm, 8: 691-709, 1989.
2. Bladessarini, Rj. and Frankenburg, F.R., Clozapine: A novel antipsychotic agent. New Engl J Med, 324: 746-754, 1991.
3. Meltzer, H.Y., Treatment-resistant schizophrenia- The role of clozapine. Curr Med Res Opin, 114: 1-20, 1997.
4. Kane, J.; Honigfeld, G.; Singer, J. and Meltzer, H., Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 45: 789-796, 1988.
5. Fitton, A. and Heel, R.C., Clozapine: a review of pharmacological properties and therapeutic use in schizophrenia. Drugs, 5: 722-725, 1990.
6. Richelson, E., Receptor pharmacology of neuroleptics: relation to clinical effects. j Clin Psychiatry, 60: 5-14,1999.
7. Lieberman, J.A., Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br J Psychiatry, 22: 7-18, 1993.
8. Jann, M.W.; Grimsley, S.R.; Gray, E.C. and Chang, W.H., Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet, 24: 161-176,1993.
9. Ackenheil, M., Clozapine-pharmacokinetic investigations and biochemical effects in man. Psychopharmacol, 99: S32-37, 1989.
10. Schaber, G.; Stevens, L.; Gaener, H.J.; Dietz, K. and Breyer-Pfaff, U., Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol, 46: 453-459, 1998.
11. Cheng, Y.F.; Lundberg, T.; Bondesson, U.; Lindstrom, L. and Gabrielsson, J., Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol, 34: 445-449, 1988.
12. Gauch, R. and Michaelis, W., The metabolism of 8-chloro-1 1-(4-methyl-i-piperazinyl)-5H-dibenzo-[b,e][1, 4]diazepine (clozapine) in mice, dogs and human subjects. Farmaco, 26: 667-681, 1971.
13. Ereshefsky, L., Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry, 57: 12-25, 1996.
14. Pokorny, R.; Finkel, M.J. and Robinson, W.T., Normal volunteers should not be used for bioavailability or bioequivalence studies of cozapine. Pharm Res, 11: 1221, 1994.
15. Levoyer, D.; Martinet, J.P.; Badiche, A. and Millet, B., Ten years of clinical experience with clozapine about 170 patients. Encephale, 30: 285-295, 2004.
16. Hagg, S.; Spigset, 0.; Bate, A. and Soderstrom, T.G., Myocarditis related to clozapine treatment. J Clin Psychopharmacol, 21: 382-388, 2001.
17. Choc, M.G.; Hsuan, F.; Honigfeld, G.; Robinson, W.T.; Ereshefsky, L.; Crismon, M.L.;S aklad, S.R.; Hirschowitz, J. and Wagner, R., Single- vs. multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res, 7: 347-351, 1990.
18. Chung, M.C.; Lin, S.K. and Chang, W.H., Determination of clozapine and desmethylclozapine in human plasma by high performance liquid chromatography with ultraviolet detection. J Chromatogr, 613: 168-173, 1993.
19. CDER, Center for Drug Evaluation and Research, US-FDA. Guidance for Industry: Clozapine tablets: In vivo bioequivalence and in vitro dissolution testing. 2003. http://www.fda.gov/cder/guidance/index.htm (Accessed 10jan 2005)
20. Choc, M.G.; Lehr, R.G.; Hsuan, F.; Honigfeld, G.; Smith, H.T.; Borison, R. and Volavka, J., Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res, 4: 402-405, 1987.
21. Lin, S.K.; Chang, W.H.; Chung, M.C.; Lam, Y.W. and Jann, M.W., Disposition of clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol, 34: 318-324, 1994.
22. Guitton, C.; Abbar, M.; Kinowski, J.M.; Chabrand, P. and Bressolle, F., Multiple-dose pharmacokinetics of dozapine in patients with chronic schizophrenia. J Clin Psychopharmacol, 18: 470-476, 1998.
23. Kluznik, J.C.; Walbek, N.H.; Farnsworth, M.G. and Melstrom, K., Clinical effects of a randomized switched of patients from clozaril to generic clozapine. J Clin Psychiatry, 62: 14-17, 2001.
24. Mofsen, R. and Balter, J., Case reports of the reemergence of psychotic symptoms after conversion from brand -name clozapine to a generic formulation. Clin Ther, 23: 1720-1731, 2001.
25. Sajbel, T.A.; Carter, G.W. and Wiley, R.B., Coverting patients from brand-name clozapine to generic clozapine. Ann Pharmacolther, 35: 281-284, 2001.
26. Makela, E.H.; Cutlip, W.D.; Stevenson, J.M.; Weimer, J.M.; Abdallah, E.S.; Akhtar, R.S.; Aboraya, A.S. and Gunel, E., Branded versus geneic clozapine for treatment of schizophrenia. Ann Pharmacolther, 37: 350-353, 2003.
27. Nuss, P.; Taylor, D.; De Hert, M. and Hummer, M., The generic alternative in schizophrenia: opportunity or treat? CNS Drugs, 18: 769-775, 2004.
28. Layton, S. and Barbeau, M., Generic replacement of clozapine: a simple decision model from a Canadian perspective. Curr Med Res Opin, 20: 453-459, 2004.